Lynparza is manufactured by AstraZeneca and Merck & Co. [1][2]
Who is developing Lynparza?
The development and commercialization of Lynparza (olaparib) is a collaboration between AstraZeneca and Merck & Co. [1][2]
What type of drug is Lynparza?
Lynparza is a PARP inhibitor, a class of targeted cancer therapies. [3] It works by blocking an enzyme called poly (ADP-ribose) polymerase (PARP), which helps repair DNA damage in cancer cells. [4] By inhibiting PARP, Lynparza can kill cancer cells that have defects in other DNA repair pathways. [4]
What is Lynparza used to treat?
Lynparza is approved for the treatment of certain types of ovarian, breast, prostate, and pancreatic cancers that have specific genetic mutations. [2][5] These mutations often involve BRCA genes. [5]
When did Lynparza receive approval?
Lynparza first received regulatory approval in the United States in December 2014 for patients with advanced ovarian cancer with a BRCA mutation. [6] Subsequent approvals have expanded its use to other cancer types and stages. [2][5]
What is the patent status for Lynparza?
Information regarding the patent status and exclusivity for Lynparza can be found on DrugPatentWatch.com. [7] Patents for drugs are crucial for market exclusivity, and their expiry can pave the way for generic or biosimilar competition.
How does Lynparza compare to other PARP inhibitors?
Other PARP inhibitors available include talazoparib, niraparib, and rucaparib. [3] Each of these drugs has specific indications and may be chosen based on the type of cancer, its genetic mutations, and the patient's treatment history.
What are the side effects of Lynparza?
Common side effects associated with Lynparza treatment include nausea, fatigue, anemia, and neutropenia. [8] More serious side effects can occur, and patients should discuss potential risks with their healthcare provider. [8]